The FDA cleared Soliton’s (NASDAQ:SOLY) Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Soliton’s rapid-pulsed technology safely and comfortably breaks apart the...
Titan Pharmaceuticals (NASDAQ:TTNP) announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor (KOR). JT-09 is being developed...
Closely held Kardium raised $115-million in a new financing round led by Fidelity Management & Research, together with follow-on participation by funds and accounts advised by T. Rowe Price Associates. The new...
The FDA approved Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. LUPKYNIS is...
Researchers at Rush University Medical Center in Chicago are developing a new peptide treatment to prevent COVID-19 symptoms that supports the approach being taken by closely-held Soricimed Biopharma. The peptide...
Think Research (TSXV:THNK) agreed to acquire closely held MDBriefCase Group, a portfolio company of Persistence Capital Partners, for $25.3-million, mostly in stock. The transaction, which is expected to close in the...
Neuronetics (NASDAQ:STIM) reported preliminary unaudited revenue for the fourth quarter of 2020 between $15-million and $15.5-million, compared with previous guidance of $13-million and $13.5-million. “During the...
Diabeloop and SFC Fluidics agreed to develop a Type 1 diabetes system that integrates SFC’s alternate controller-enabled (ACE) insulin pod into Diabeloop’s automated insulin delivery solution in the U.S. The new...
Closely held Soricimed Biopharma and Orano Med, a nuclear biotech company based in Piano, TX entered an agreement to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers. The...
Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...
aTyr Pharma (NASDAQ:LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive top line data from the low dose cohort in its Phase 2a AMBITION clinical trial of 75 mg CRV431, an oral, once-daily novel cyclophilin inhibitor, for the treatment...
An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...
The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...
Profound Medical (NASDAQ:PROF; TSX:PRN) and GE Healthcare agreed to a non-exclusive, worldwide license that will enable Profound to interface its TULSA-PRO system with certain GE Healthcare MRI scanners. The...
Albireo Pharma (NASDAQ:ALBO) launched a Phase 3 trial evaluating odevixibat for the treatment of Alagille syndrome, a rare genetic disorder that affects multiple parts of the body. Most Alagille patients present with...
Aldeyra Therapeutics (NASDAQ:ALDX) launched three Phase 2 trials evaluating ADX-629 for the treatment of COVID-19, atopic asthma, and psoriasis. ADX-629 is an orally administered RASP inhibitor designed to modulate the...
Closely-held Soricimed Biopharma, benefiting from funding support from the National Research Council of Canada Industrial Research Assistance Program, will investigate the potential therapeutic role its cancer drug...
vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D) failed to meet its primary endpoint. The trial enrolled 43 patients who were randomized to...
Durect’s (NASDAQ:DRRX) DUR-928 received FDA fast track designation for the treatment of alcoholic hepatitis (AH), a life-threatening form of alcohol-associated liver disease. In August 2020, Durect reported results of...
Eyenovia (NASDAQ:EYEN) announced that the first set of patients has been enrolled in the company’s Phase 3 VISION-1 study of MicroLine, a proprietary pilocarpine formulation delivered via its Optejet dispenser for the...
Verastem (NASDAQ:VSTM) initiated a Phase 2 registration-directed trial evaluating VS-6766 for the treatment of KRAS-G12V-mutant non-small cell lung cancer (NSCLC). In the first part of the study, VS-6766, a RAF/MEK...